drugset / Trial / NCT04915586
Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.
Timeline
- Start
- 2019-12-30
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 16 mg | — |
| Subject | dornase alfa | Protein / enzyme biologic | 5 mg | — |